Oncology

Investigators: Same-Day Pegfilgrastim Is Safe and Effective in Patients Receiving CTX for Breast, Lung Cancer

June 15th 2021

By Tony Hagen

Same-day pegfilgrastim to combat febrile neutropenia in conjunction with myelosuppressive chemotherapy (CTX) is safe, investigators conclude.

Celltrion Reports Positive Real-World Findings for Truxima in DLBCL

June 14th 2021

By Tony Hagen

Postmarketing retrospective studies of the rituximab biosimilar (CT-P10, Truxima) demonstrated comparable safety and efficacy for treatment of diffuse large B-cell lymphoma (DLBCL).

Opinion: Biosimilars Offer Savings and Access for US Patients

June 12th 2021

By Meaghan Smith

In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.

Part 2: Panelists Advise Patterning Guidelines on International Standards

June 11th 2021

In part 2 of this panel discussion, 3 experts on India’s biologics industry discuss whether biosimilars can be produced affordably in the country and ways of improving the industry’s image.

Matrix Report Identifies Shortcomings of US Patent System

June 10th 2021

By Tony Hagen

The European Union makes it far more difficult to obtain patents on biologics, reducing the likelihood of patent “thickets” that stifle competition, the Matrix Global Advisors report states.

Part 1: Panelists Suggest More Groundwork Is Needed for Indian Biologics to Achieve Global Market Access

June 9th 2021

In part 1 of this panel discussion, 3 experts on India’s biologics industry explain what’s missing from current biosimilar regulation and what the country needs to do for its products to compete internationally.

Poll: Identify the Main Cause for Reverse Switching

June 8th 2021

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

Study: OCM Reduces Use of Some Supportive Care Medications and Boosts Filgrastim Biosimilar Use

June 8th 2021

By Tony Hagen

Investigators noted a reduction in use of high-cost supportive care agents, suggesting that the value-based Oncology Care Model (OCM) is working.

Ogivri Equivalence Demonstrated in Neoadjuvant HER2+ Comparative Trial

June 7th 2021

By Tony Hagen

Investigators further elucidate the equivalence of a trastuzumab biosimilar vs Herceptin in human epidermal growth factor receptor 2–positive (HER2+) breast cancer.

Study Suggests Oncologists' Use of Biosimilars Grew From Trickle to Flood

June 6th 2021

By Tony Hagen

When biosimilars emerged in oncology, oncologists dipped in a toe and then got serious, according to a retrospective study on usage and savings presented at ASCO 2021.